The strategic elements enabling Glycon to achieve its stated mission are:

  • The commercial market opportunities targeted by Glycon are more than sufficient to attract licensing and/or cooperative development agreements with leading pharmaceutical companies.

  • The development strategy consists of using its patented platform technologies in developing new pro-drugs, new delivery systems for pharmaceuticals and new compositions of matter useful in prescription and non-prescription drugs.

  • Each platform technology has multiple drug candidates thereby optimizing opportunities for successful pharmaceutical partnering.

  • Glycon continues to seek licensing and/or cooperative development agreements with pharmaceutical companies.

Glycon is actively seeking licensing and or co-development partners for the continued development of its potential drug candidates. 

For information, contact:
Mike Allen 
Tel: (205) 405-4114